An update on ripasudil for the treatment of glaucoma and ocular hypertension

被引：15

作者：

Testa, V ^{[1
,2
]}

Desideri, L. Ferro ^{[1
,2
]}

Della Giustina, P. ^{[1
,2
]}

Traverso, C. E. ^{[1
,2
]}

Iester, M. ^{[1
,2
]}

机构：

[1] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy

[2] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy

来源：

DRUGS OF TODAY | 2020年 / 56卷 / 09期

关键词：

Ripasudil; Rho-associated protein kinase (ROCK) inhibitors; Glaucoma; Ocular hypertension; Ophthalmic drugs; RHO-KINASE INHIBITOR; OPEN-ANGLE GLAUCOMA; FUCHS ENDOTHELIAL DYSTROPHY; EYE DROP RIPASUDIL; INTRAOCULAR-PRESSURE; ROCK INHIBITOR; TRABECULAR MESHWORK; K-115; H-7; CONTRACTION;

D O I：

10.1358/dot.2020.56.9.3178110

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ripasudil (K-115) is a novel Rho-associated protein kinase (ROCK) inhibitor. The Rho-ROCK pathway regulates key downstream effectors involved in many cellular functions, in particular in the actin cytoskeleton activity. The clinical effects of ripasudil expected on the eye include an intraocular pressure-lowering effect and a wound-healing activity on corneal endothelial cells, but many other functions are currently under investigation. To date, ripasudil has been approved in Japan (2014) for the treatment of glaucoma and ocular hypertension, and several clinical trials are currently investigating its role in the treatment of Fuchs' corneal dystrophy. In this review, we will discuss its pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.

引用

页码：599 / 608

页数：10

共 50 条

[31] Accuracy of ophthalmologists in predicting glaucoma from ocular hypertension based on the results of the Ocular Hypertension Treatment Study (OHTS)
Mansberger, SL
Cioffi, GA
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U676 - U676
[32] One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension
Tanihara, Hidenobu
Inoue, Toshihiro
Yamamoto, Tetsuya
Kuwayama, Yasuaki
Abe, Haruki
Fukushima, Atsuki
Suganami, Hideki
Araie, Makoto
ACTA OPHTHALMOLOGICA, 2016, 94 (01) : E26 - E34
[33] A REVISIT - OCULAR HYPERTENSION, GLAUCOMA SUSPECT, PREGLAUCOMA, OR GLAUCOMA
SHIELDS, MB
ANNALS OF OPHTHALMOLOGY, 1985, 17 (08): : 456 - 456
[34] A REVISIT - OCULAR HYPERTENSION, GLAUCOMA SUSPECT, PREGLAUCOMA, OR GLAUCOMA
JOHNSON, TD
ZIMMERMAN, TJ
ANNALS OF OPHTHALMOLOGY, 1985, 17 (07): : 390 - 391
[35] Ripasudil in a Model of Pigmentary Glaucoma
Wang, Chao
Dang, Yalong
Waxman, Susannah
Hong, Ying
Shah, Priyal
Loewen, Ralitsa T.
Xia, Xiaobo
Loewen, Nils A.
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2020, 9 (10): : 1 - 8
[36] Ocular Surface Disease in Patients with Ocular Hypertension and Glaucoma
Stewart, William C.
Stewart, Jeanette A.
Nelson, Lindsay A.
CURRENT EYE RESEARCH, 2011, 36 (05) : 391 - 398
[37] Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment
Bron, A
Nordmann, JP
Rouland, JF
Baudouin, C
Sartral, M
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2006, 29 (02): : 164 - 168
[38] Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: Are they really the same?
Golan, Shani
Rosenfeld, Eldar
Shemesh, Gabi
Kurtz, Shimon
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (02) : 220 - 224
[39] Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study
Singh, Rishabh K.
Zhao, Yan
Elze, Tobias
Fingert, John
Gordon, Mae
Kass, Michael A.
Luo, Yuyang
Pasquale, Louis R.
Scheetz, Todd
Segre, Ayellet V.
Wiggs, Janey L.
Zebardast, Nazlee
JAMA OPHTHALMOLOGY, 2024, 142 (04) : 356 - 363
[40] Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France
Bron, A
Nordmann, JP
Baudouin, C
Rouland, JF
Kadi, A
Sartral, M
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2003, 26 (09): : 895 - 903

← 1 2 3 4 5 →